Articles

Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response

Baerveldt, E.M.
Onderdijk, A.J.
Kurek, D.
Kant, M.
Florencia, E.F.
Ijpma, A.S.
Spek, P.J. van der
Bastiaans, J.
Jansen, P.A.M.
Kilsdonk, J.W.J. van
Laman, J.D.
Prens, E.P.

January 2013

BACKGROUND: Ustekinumab is a fully human anti-p40 monoclonal antibody which neutralizes interleukin ...

Ustekinumab improves psoriasis without altering T cell cytokine production, differentiation, and T cell receptor repertoire diversity.

Kenshiro Tsuda
Keiichi Yamanaka
Makoto Kondo
Kimiko Matsubara
Ryogen Sasaki
Hidekazu Tomimoto
Esteban C Gabazza
Hitoshi Mizutani

Ustekinumab is a fully human IgG1κ monoclonal antibody targeting interleukin (IL)-12/23 p40 subunit....

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

Kavanaugh, A.
Ritchlin, C.
Rahman, P.
Puig, L.
Gottlieb, A.B.
Li, S.
Wang, Y.
Noonan, L.
Brodmerkel, C.
Song, M.
Mendelsohn, A.M.
McInnes, I.B.

January 2014

Objective: Evaluate ustekinumab, an anti-interleukin (IL)-12 and IL-23 antibody, effects on radiogra...

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Leonardi, Craig L
Kimball, Alexa B
Papp, Kim A
Yeilding, Newman
Guzzo, Cynthia
Wang, Yuhua
Li, Shu
Dooley, Lisa T
Gordon, Kenneth B
Ghislain, Pierre-Dominique

January 2008

Background: interleukins 12 and 23 have important roles in the pathophysiology of psoriasis. We asse...

Ustekinumab for the treatment of psoriatic arthritis: an update

Davari, Parastoo
Leo, Michael S
Kamangar, Faranak
Fazel, Nasim

January 2014

Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in som...

Correspondence to

Handling Tore
K Kvien
Immunology Rheumatology
Rahman P
Kavanaugh A

January 2014

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with acti...

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

Ritchlin, C.
Rahman, P.
Kavanaugh, A.
McInnes, I.B.
Puig, L.
Li, S.
Wang, Y.
Shen, Y.-K.
Doyle, M. K.
Mendelsohn, A. M.
Gottlieb, A. B.
Perate, M.
Whitman, M.
Dooley, L. T.
Alten, R.
Birbara, C.
Boh, E.
Braun, J.
Budd, J.
Chattapadhyay, C.
Chudzik, D.
Claudepierre, P.
Cooper, R.
Drescher, E.
Dutz, J.
Edwards, C.
Elewski, B.
El-Kadi, H.
Erlacher, L.
Flipo, R.
Fretzin, S.
George, E.
Gladstein, G.
Griffin, R.
Grisanti, M.
Guenther, L.
Gulliver, W.
Hobbs, K.
Huang, E.
Ilivanova, E.
Jeka, S.
Khraishi, M.
Kokhan, M.
Korman, N.
Kunynetz, R.
Leonardi, C.
Lessard, C.
Lindquist, U.
Martin, A.
Matheson, R.
Murphy, F.
Nasonov, E.
Palmer, W.
Papp, K.
Rech, J.
Rell-Bakalarska, M.
Rich, P.
Rosen, C.
Rudin, A.
Ruppert-Roth, A.
Scheinecker, C.
Seigel, S.
Shaikh, S.
Sheeran, T.
Shergy, W.
Siegel, E.
Sierakowski, S.
Sofen, H.
Szanto, S.
Tahir, H.
Telegdy, E.
Toth, D.
Walker, D.
Wilson, A.
Witt, M.
Wollenhaupt, J.
Zoschke, D.
Zubrzycka, A.

January 2014

Objective: Assess ustekinumab efficacy (week 24/week 52) and safety (week 16/week 24/week 60) in pat...

Ustekinumab : a review of the effectiveness of targeting interleukin-12/23P40 in psoriasis and other immune-mediated diseases

Swendrowski, Nicholas Patrick

May 2013

Interleukin-12 (IL-12) and interleukin-23(IL-23) are cytokines that have been shown to have a role ...

Novel biologic therapies in development targeting IL-12/IL-23.

Kerkhof, P.C.M. van de

January 2010

Contains fulltext : 89886.pdf (publisher's version ) (Closed access)Recent researc...

The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting

Menting, S. P.
van den Reek, J. M. P. A.
Baerveldt, E. M.
de Jong, E. M. G. J.
Prens, E. P.
Lecluse, L. L. A.
Wolbink, G. J.
van der Kleij, D.
Spuls, Ph I.
Rispens, T.

January 2015

Several therapeutic antibodies are available for the treatment of chronic plaque type psoriasis. Ust...

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis

Haugh IM
Preston AK
Kivelevitch DN
Menter AM

November 2018

Isabel M Haugh,1 Allie K Preston,2 Dario N Kivelevitch,1 Alan M Menter1 1Department of Dermatology,...

Association of Serum Ustekinumab Levels with Clinical Response in Psoriasis

Tsakok, Teresa
Wilson, Nina
Dand, Nick
Loeff, Floris C.
Bloem, Karien
Baudry, David
Duckworth, Michael
Pan, Shan
Pushpa-Rajah, Angela
Standing, Joseph F.
de Vries, Annick
Alsharqi, Ali
Becher, Gabrielle
Murphy, Ruth
Wahie, Shyamal
Wright, Andrew
Griffiths, Christopher E. M.
Reynolds, Nick J.
Barker, Jonathan
Warren, Richard B.
Burden, A. David
Rispens, Theo
Stocken, Deborah
Smith, Catherine

January 2019

Importance: High-cost biologic therapies have transformed the management of immune-mediated inflamma...

Emerging treatments in the management of psoriasis: biological targeting with ustekinumab

Papoutsaki, M
COSTANZO, ANTONIO
CHIMENTI, SERGIO

January 2009

Psoriasis is a chronic, genetically determined, immune-mediated, inflammatory skin disease affecting...

Use of Ustekinumab in the Treatment of Libyan Psoriasis Vulgaris Patients

Beltammer Belkais
Gargoom Ali
Taeib Ghada
Duweb Gamal

March 2019

Introduction. Psoriasis is a relatively common chronic inflammatory disease. It clinically manifests...

Ustekinumab Improves Psoriasis without Altering T Cell Cytokine Production, Differentiation, and T Cell Receptor Repertoire Diversity

Kenshiro Tsuda (110951)
Keiichi Yamanaka (110955)
Makoto Kondo (110958)
Kimiko Matsubara (110962)
Ryogen Sasaki (110967)
Hidekazu Tomimoto (110968)
Esteban C. Gabazza (110970)
Hitoshi Mizutani (110972)

December 2012

<div><p>Ustekinumab is a fully human IgG1κ monoclonal antibody targeting interleukin (IL)-12/23 p40 ...

Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response

Baerveldt, E.M.
Onderdijk, A.J.
Kurek, D.
Kant, M.
Florencia, E.F.
Ijpma, A.S.
Spek, P.J. van der
Bastiaans, J.
Jansen, P.A.M.
Kilsdonk, J.W.J. van
Laman, J.D.
Prens, E.P.

January 2013

BACKGROUND: Ustekinumab is a fully human anti-p40 monoclonal antibody which neutralizes interleukin ...

Ustekinumab improves psoriasis without altering T cell cytokine production, differentiation, and T cell receptor repertoire diversity.

Kenshiro Tsuda
Keiichi Yamanaka
Makoto Kondo
Kimiko Matsubara
Ryogen Sasaki
Hidekazu Tomimoto
Esteban C Gabazza
Hitoshi Mizutani

Ustekinumab is a fully human IgG1κ monoclonal antibody targeting interleukin (IL)-12/23 p40 subunit....

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

Kavanaugh, A.
Ritchlin, C.
Rahman, P.
Puig, L.
Gottlieb, A.B.
Li, S.
Wang, Y.
Noonan, L.
Brodmerkel, C.
Song, M.
Mendelsohn, A.M.
McInnes, I.B.

January 2014

Objective: Evaluate ustekinumab, an anti-interleukin (IL)-12 and IL-23 antibody, effects on radiogra...

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Leonardi, Craig L
Kimball, Alexa B
Papp, Kim A
Yeilding, Newman
Guzzo, Cynthia
Wang, Yuhua
Li, Shu
Dooley, Lisa T
Gordon, Kenneth B
Ghislain, Pierre-Dominique

January 2008

Background: interleukins 12 and 23 have important roles in the pathophysiology of psoriasis. We asse...

Ustekinumab for the treatment of psoriatic arthritis: an update

Davari, Parastoo
Leo, Michael S
Kamangar, Faranak
Fazel, Nasim

January 2014

Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in som...

Correspondence to

Handling Tore
K Kvien
Immunology Rheumatology
Rahman P
Kavanaugh A

January 2014

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with acti...

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

Ritchlin, C.
Rahman, P.
Kavanaugh, A.
McInnes, I.B.
Puig, L.
Li, S.
Wang, Y.
Shen, Y.-K.
Doyle, M. K.
Mendelsohn, A. M.
Gottlieb, A. B.
Perate, M.
Whitman, M.
Dooley, L. T.
Alten, R.
Birbara, C.
Boh, E.
Braun, J.
Budd, J.
Chattapadhyay, C.
Chudzik, D.
Claudepierre, P.
Cooper, R.
Drescher, E.
Dutz, J.
Edwards, C.
Elewski, B.
El-Kadi, H.
Erlacher, L.
Flipo, R.
Fretzin, S.
George, E.
Gladstein, G.
Griffin, R.
Grisanti, M.
Guenther, L.
Gulliver, W.
Hobbs, K.
Huang, E.
Ilivanova, E.
Jeka, S.
Khraishi, M.
Kokhan, M.
Korman, N.
Kunynetz, R.
Leonardi, C.
Lessard, C.
Lindquist, U.
Martin, A.
Matheson, R.
Murphy, F.
Nasonov, E.
Palmer, W.
Papp, K.
Rech, J.
Rell-Bakalarska, M.
Rich, P.
Rosen, C.
Rudin, A.
Ruppert-Roth, A.
Scheinecker, C.
Seigel, S.
Shaikh, S.
Sheeran, T.
Shergy, W.
Siegel, E.
Sierakowski, S.
Sofen, H.
Szanto, S.
Tahir, H.
Telegdy, E.
Toth, D.
Walker, D.
Wilson, A.
Witt, M.
Wollenhaupt, J.
Zoschke, D.
Zubrzycka, A.

January 2014

Objective: Assess ustekinumab efficacy (week 24/week 52) and safety (week 16/week 24/week 60) in pat...

Ustekinumab : a review of the effectiveness of targeting interleukin-12/23P40 in psoriasis and other immune-mediated diseases

Swendrowski, Nicholas Patrick

May 2013

Interleukin-12 (IL-12) and interleukin-23(IL-23) are cytokines that have been shown to have a role ...

Novel biologic therapies in development targeting IL-12/IL-23.

Kerkhof, P.C.M. van de

January 2010

Contains fulltext : 89886.pdf (publisher's version ) (Closed access)Recent researc...

The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting

Menting, S. P.
van den Reek, J. M. P. A.
Baerveldt, E. M.
de Jong, E. M. G. J.
Prens, E. P.
Lecluse, L. L. A.
Wolbink, G. J.
van der Kleij, D.
Spuls, Ph I.
Rispens, T.

January 2015

Several therapeutic antibodies are available for the treatment of chronic plaque type psoriasis. Ust...

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis

Haugh IM
Preston AK
Kivelevitch DN
Menter AM

November 2018

Isabel M Haugh,1 Allie K Preston,2 Dario N Kivelevitch,1 Alan M Menter1 1Department of Dermatology,...

Association of Serum Ustekinumab Levels with Clinical Response in Psoriasis

Tsakok, Teresa
Wilson, Nina
Dand, Nick
Loeff, Floris C.
Bloem, Karien
Baudry, David
Duckworth, Michael
Pan, Shan
Pushpa-Rajah, Angela
Standing, Joseph F.
de Vries, Annick
Alsharqi, Ali
Becher, Gabrielle
Murphy, Ruth
Wahie, Shyamal
Wright, Andrew
Griffiths, Christopher E. M.
Reynolds, Nick J.
Barker, Jonathan
Warren, Richard B.
Burden, A. David
Rispens, Theo
Stocken, Deborah
Smith, Catherine

January 2019

Importance: High-cost biologic therapies have transformed the management of immune-mediated inflamma...

Emerging treatments in the management of psoriasis: biological targeting with ustekinumab

Papoutsaki, M
COSTANZO, ANTONIO
CHIMENTI, SERGIO

January 2009

Psoriasis is a chronic, genetically determined, immune-mediated, inflammatory skin disease affecting...

Use of Ustekinumab in the Treatment of Libyan Psoriasis Vulgaris Patients

Beltammer Belkais
Gargoom Ali
Taeib Ghada
Duweb Gamal

March 2019

Introduction. Psoriasis is a relatively common chronic inflammatory disease. It clinically manifests...

Ustekinumab Improves Psoriasis without Altering T Cell Cytokine Production, Differentiation, and T Cell Receptor Repertoire Diversity

Kenshiro Tsuda (110951)
Keiichi Yamanaka (110955)
Makoto Kondo (110958)
Kimiko Matsubara (110962)
Ryogen Sasaki (110967)
Hidekazu Tomimoto (110968)
Esteban C. Gabazza (110970)
Hitoshi Mizutani (110972)

December 2012

<div><p>Ustekinumab is a fully human IgG1κ monoclonal antibody targeting interleukin (IL)-12/23 p40 ...

Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response

Baerveldt, E.M.
Onderdijk, A.J.
Kurek, D.
Kant, M.
Florencia, E.F.
Ijpma, A.S.
Spek, P.J. van der
Bastiaans, J.
Jansen, P.A.M.
Kilsdonk, J.W.J. van
Laman, J.D.
Prens, E.P.

January 2013

BACKGROUND: Ustekinumab is a fully human anti-p40 monoclonal antibody which neutralizes interleukin ...

Ustekinumab improves psoriasis without altering T cell cytokine production, differentiation, and T cell receptor repertoire diversity.

Kenshiro Tsuda
Keiichi Yamanaka
Makoto Kondo
Kimiko Matsubara
Ryogen Sasaki
Hidekazu Tomimoto
Esteban C Gabazza
Hitoshi Mizutani

Ustekinumab is a fully human IgG1κ monoclonal antibody targeting interleukin (IL)-12/23 p40 subunit....

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

Kavanaugh, A.
Ritchlin, C.
Rahman, P.
Puig, L.
Gottlieb, A.B.
Li, S.
Wang, Y.
Noonan, L.
Brodmerkel, C.
Song, M.
Mendelsohn, A.M.
McInnes, I.B.

January 2014

Objective: Evaluate ustekinumab, an anti-interleukin (IL)-12 and IL-23 antibody, effects on radiogra...

Abstract

Extracted data

Related items

Related items